ASCO Data Looms Over BioNTech as Shareholders Back Management but Markets Stay Cold

BioNTech shares slide 8% monthly, trade below moving averages despite board support. Revenue drops 35%, buyback fails to lift stock. All eyes on ASCO data for Pumitamig.

The message from the annual general meeting was clear: shareholders are willing to give BioNTech time to reinvent itself. But the stock market isn't feeling generous. The Mainz-based biotech closed Friday at €76.95, slipping 2.22% on the day and marking a monthly decline of just over 8%. The shares are now trading comfortably below both the 50-day and 200-day moving averages — the gap to the long-term line exceeds 11%. For a company with a billion-dollar stock buyback program authorised but barely making a dent, the technical picture is unmistakably bearish.

A Board Endorsement That Speaks Volumes

The AGM, held on 15 May 2026, drew a formidable 92% of voting capital. Every management proposal passed without dissent, including a controversial plan to enlarge the supervisory board from its current size to eight members. The expansion is more than procedural — BioNTech is navigating a strategic pivot away from a pandemic-era dependence on Covid-19 revenues toward an oncology-first identity built on its immunotherapy pipeline. Board refreshment and governance alignment are part of that story.

Revenues Keep Shrinking as the Outlook Holds Steady

First-quarter revenues slumped to €118.1 million from €182.8 million a year earlier, a 35% drop that underscores just how fast the old revenue base is eroding. Management is sticking to its full-year guidance of $2.3 billion to $2.6 billion. That range implies a significant ramp-up in the remaining three quarters — a bet that depends entirely on the clinical narrative shifting decisively in BioNTech’s favour.

To backstop the stock, the company has authorised a share repurchase programme worth up to $1.0 billion. So far, the buyback’s effect has been underwhelming. The stock remains near its year-low, and analysts point a finger at the big gap between pipeline promise and current balance-sheet reality.

The Analyst Split: Optimism vs. Conservatism

Wall Street is deeply divided. Canaccord Genuity maintains a Buy rating and a $158 price target, citing the potential of BioNTech’s late-stage oncology assets. Leerink Partners is far more cautious, valuing the stock at $94 — a level that would still imply roughly 22% upside from Friday’s close but hardly a ringing endorsement. The spread between the two targets reveals how much the valuation hinges on the next set of hard data.

Pumitamig Gets Its Day in the Data Spotlight

That data arrives at the American Society of Clinical Oncology (ASCO) meeting, running from 29 May to 2 June. BioNTech will present Phase 2 results from the ROSETTA-Lung-02 study, which evaluates its lead candidate Pumitamig in combination with chemotherapy against the standard-of-care Pembrolizumab plus chemotherapy in lung cancer patients. The head-to-head comparison is the kind of pivotal readout that can reshape — or reset — the company’s oncology narrative.

A positive outcome would bolster the case that BioNTech can evolve from a single-product vaccine manufacturer into a diversified immuno-oncology player. A miss would deepen the scepticism that has weighed on the stock for months. Between now and the ASCO presentation, the share price is likely to remain technically fragile, bouncing between the buyback floor and the uncertainty ceiling set by the looming trial results.